GW Pharmaceuticals is a biopharmaceutical company focused to discover therapeutics from cannabinoids and effectively cover a range of diseases.
The main focus on the company is their seizure treatment product known as Epidiolex. The Food and Drug Administration (FDA) set a Prescription Drug User Free Act (PUFDA) date on June 27th, 2018.
GW Pharmaceuticals announced on March 13th that the company has a receipt of Notices of Allowances on five new Epidiolex patents. These new patents, if the NDA is approved, will expire in 2035. The patents are possibly eligible for additional years with patent adjustments and/or exclusives within regulations.
These patent applications will be listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (ADPTEE) when the NDA for Epidiolex gets approval.
Epidiolex will also receive New Chemical entity exclusivity status as the FDA has given Orphan Drug Designation for the use of Epidiolex to treat seizures associated with several illnesses and diseases.
The patent news for GW Pharmaceuticals brought the stock to the highest price of the month at $122.64 on March 14th. The stock currently trades, after market close on the 15th, at a 2.67% decrease in value.